Abstracts Clinical Lymphoma, Myeloma & Leukemia September 2023 S348 laboratory able to express the results according to the International Scale (Hugues T, et al. Blood. 2006;108:28-37). LDRpro schedule was a dose reduction between 25% and 66% of the standard 400mg dose and higher doses such as 600 mg and 800 mg. Of a total of 61 patients of 160 (38.1%), 4 were excluded, 1 was lost during the follow-up and 3 deaths were not related to CML. Fifty-seven patients are the study group whose demographics are: admission age 37 (14-67), actual age 52 (29-80), and survival (in years) 13 (823). The LDRpro started in January 2017 and the update results in April 2023. The median time of CML duration was 14 (8-22) years. Dose reduction was: for 25%, 10 patients with 6 cases of relapse, 33%, 9 patients with 3 cases of relapse, 50%, 36 patients with 5 cases of relapse, and 66%, 2 patients without relapse. The relapse rate was 14/57 (24.5%). LDR pro is an interesting alternative for optimizing CML Ph+ IMA treatment with 7 years of MMR with a 24.5% relapse rate, which is lower compared with previous reports. Relapses were mild (1- to 2-log) for the majority and respond to the initial dose. The most important benefit is the median time survival of 13 years since the initial diagnosis. Keywords: CML, low dose, imatinib, Philadelphia chromosome CML-562 The Importance of Quality of Survivorship: US Results From the Chronic Myeloid Leukemia (CML) Survey on Unmet Needs (SUN) Joannie Clements1, Cristina Ruiz1, Andrea Damon PhD2, Peter Schuld PhD3, Pauline Frank MS3, Cristina Constantinescu MA4, Jorge Cortes MD5 1CML Buster Foundation, Costa Mesa, USA. 2Novartis Pharmaceuticals Corporation, East Hanover, USA. 3Novartis Pharma AG, Basel, Switzerland. 4Ipsos, Basel, Switzerland. 5Georgia Cancer Center, Augusta, USA Background: Advances in CML treatment have improved patients’ life expectancy; still, resistance/intolerance negatively impact outcomes. Reports of patient and physician unmet needs are lacking. Here, we report US data from CML SUN, a survey conducted with patients and physicians to understand unmet needs around CML. Methods: CML SUN was conducted online among patients aged ≥18 years with chronic-phase CML (CML-CP) receiving second- or later-line tyrosine kinase inhibitor (TKI) therapy and physicians (hematologists and/or oncologists) who treated ≥10 patients with CML-CP over the past year to comprehensively understand the unmet needs around CML from the perspectives of patients and physicians. Results: 361 patients and 198 physicians in 11 countries participated; 70 and 30, respectively, were from the US (reported here). The most important information patients want to receive at diagnosis is the impact of CML on their lives and potential side effects (SEs) of treatment; however, ≥40% of physicians do not discuss this information. Maintaining/improving quality of life (QOL) and achieving major molecular response are among the top treatment goals for both patients and physicians. While patients are generally satisfied with how treatments work to control their disease (86%), many are not satisfied with their QOL (34%), including SEs (49%) and the impact of treatment on their mental health (50%), social life (47%), financial situation (43%), and work life (37%). Patients (81%) and physicians (76%) worry about the long-term effects of treatment on overall health. SEs often cause treatment switching and are one of the top 3 reasons for noncompliance (along with forgetting and wanting to feel normal during a holiday/ event). Of patients who informed their physician of and switched treatment due to SEs, only 27%-29% felt empathy from their physician, and up to 29% reported that their physician felt that their SEs were not serious and expected them to continue treatment. Conclusion: Patients with CML require long-term treatment with TKIs, making the quality of survivorship an important part of the patient experience. QOL and SEs are major challenges for patients, with SEs often leading to treatment switching and noncompliance. Treatment options that preserve QOL without sacrificing efficacy are needed. Keywords: CML SUN, TKI, patient-reported outcomes, unmet needs CML-573 ASC2ESCALATE: A US, Phase II Open‑Label, Single‑Arm, Dose‑Escalation Study of Asciminib Monotherapy in Second‑Line (2L) and First‑Line (1L) Treatment of Patients With Chronic Myeloid Leukemia in Chronic Phase (CML‑CP) Ehab Atallah MD1, Michael Mauro MD2, Koji Sasaki MD3, Moshe Levy MD4, Paul Koller MD5, Daisy Yang PharmD6, Dramane Laine PhD6, John Sabo MS6, Ennan Gu PhD7, Jorge Cortes MD8 1Medical College of Wisconsin, Milwaukee, USA. 2Memorial Sloan Kettering Cancer Center, New York, USA. 3The University of Texas MD Anderson Cancer Center, Houston, USA. 4Baylor Scott & White Health, Dallas, USA. 5City of Hope National Medical Center, Duarte, USA. 6Novartis Pharmaceuticals Corporation, East Hanover, USA. 7Novartis Pharmaceuticals Corporation, Cambridge, USA. 8Georgia Cancer Center, Augusta, USA Context: ATP-competitive tyrosine kinase inhibitors (TKIs) have significantly improved survival in CML, yet many patients discontinue 1L therapy due to resistance/intolerance and switch to 2L therapy, to which resistance is typically higher. Effective, safe options are needed in 2L and 1L. Asciminib, the first BCR::ABL1 inhibitor Specifically Targeting the ABL Myristoyl Pocket (STAMP), has activity against most BCR::ABL1 mutations associated with resistance to ATP-competitive TKIs, potentially providing a new 2L and/or 1L treatment. Asciminib has demonstrated efficacy/ safety across a wide dose range. Objective: Evaluate efficacy/safety of asciminib in 2L and 1L patients with CML-CP. Design: US-based phase II, open-label, multicenter, single-arm, dose-escalation study. The 2L cohort includes adults with non-T315I mutated CML-CP with 1 prior ATP-competitive TKI discontinued for warning response (BCR::ABL1IS >1%–10% after 6 months or >0.1%–1% after 12 months of 1L treatment), resistance (BCR::ABL1IS >10% with 6-12 months or >1% or loss of major molecular response [MMR] with
RkJQdWJsaXNoZXIy MTk3NTQxMg==